7-Year experience in usage of mirapex in patients with different forms of primary parkinsonism

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 106, Issue 11, 2006, Pages 26-32

  Illarioshkin, S N ^a   Ivanova Smolenskaya, I A ^a   Zagorovskaya, T B ^a   Karabanov, A V ^a   Poleshchuk, V V ^a   Markova, E D ^a   Karpova, E A ^a   Polevaya, E V ^a   Bagyeva, G Kh ^a   Timerbaeva, S L ^a   Nurmanova, Sh A ^a  

^a NONE

Author keywords

Mirapex; Primary parkinsonism; Treatment

Indexed keywords

EID: 33845952540     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 2003; 61: Suppl 3: S12-S16.
9. Goetz C.G., Poewe W., Rascal O., Sampaio C. Evidence-based medical review update: pharmacological ans surgical treatments of Parkinson's disease: 2001 to 2004. Mov Dis 2005; 20: 523-539.
10. Hughes A.J., Daniel S.E., Kilford I., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiat 1992; 55: 181-184.
11. Ishikawa A., Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996; 47: 160-166.
12. Kitada T., Asakawa S., Hattori N. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
13. Koller W.C. Silver D.E., Lieberman A. et al. An algorithm for the management of Parkinson's disease. Neurology 1994; 44: Suppl 10: S1-S52.
14. Koller W.C., Hutton J.T., Tolosa E., Capilldeo R. Immediate-release and controlled release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999; 53: 1012-1019.
15. Lücking C.B., Dürr A., Bonifati V. et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. New Engl J Med 2000; 342: 1560-1567.
16. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiat 1994; 57: 672-681.
17. Mizuno Y., Yanagisawa N., Kuno S. et al. Randomized, double-blind study of prami pexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Dis 2003; 18: 1149-1156.
18. Narabayashi H., Yokoshi M., Lizuka R., Nagatsu T. Juvenile parkinsonism. In: Handbook of clinical neurology. P.J. Vinken, G.W. Bruyn, H.L. Klawans (eds.). Amsterdam: Elsevier Science Publ 1986; 49: 153-165.
19. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
20. Whone A.L., Watts R.L., Stoessl A.J. et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
21. Wong K.S., Lu S.-C., Shan D.-E. et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003; 216: 81-87.